Iconovo receives a significant order from Japanese TOA Pharmaceuticals Co., Ltd.

The innovative Swedish medical technology provider Iconovo AB announced today that the company has received a significant order from the Japanese TOA Pharmaceuticals Co., Ltd. ICONOVO will develop several devices for APIs in several disease areas including respiratory.

The order is the next important step in the collaboration between the two companies that began in April 2017. The project is a pilot study and a so-called proof-of-concept project. If the results of the preliminary study are satisfactory, the parties intend to expand their cooperation to develop one or more commercial products. When the products are available in the market, Iconovo AB will receive royalties based on sales.

"This is an important step forward in our cooperation with TOA Pharmaceuticals. Iconovos produkts are very well suited for many markets special requirements and we are very pleased to be able to test and validate this. We expect this pilot study to help us achieve our goals and pave the way for several new projects in the coming years," says Orest Lastow, CEO of Iconovo. Read more www.iconovo.se

Iconovo AB